3-氯-5-甲基-2-噻吩甲酸 | 229343-22-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 3-氯-5-甲基-2-噻吩甲酸
• 中文别名: 3-氯-5-甲基噻吩-2-甲酸
• 英文名称: 3-chloro-5-methyl-2-thiophenecarboxylic acid
• 英文别名: 3-chloro-5-methylthiophene-2-carboxylic acid
• CAS: 229343-22-0
• 化学式: C₆H₅ClO₂S
• mdl: MFCD08695654
• 分子量: 176.624
• InChiKey: BVJIMVUEBVROJS-UHFFFAOYSA-N

物化性质

• 沸点：
  300.8±37.0 °C(Predicted)
• 密度：
  1.475±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-氯-5-甲基-2-噻吩甲酸 在 吡啶 、 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 46.0h， 生成 3-chloro-N-{4-chloro-2-[(4-chlorophenyl)carbamoyl]phenyl}-5-(morpholin-4-ylmethyl)thiophene-2-carboxamide
  参考文献：
  名称：

  Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa

  摘要：

  A series of thiophene-containing non-amidine factor Xa inhibitors is described. Simple methyl-substituted thiophene analogs were relatively weak inhibitors. However, introduction of hydrophilic substituents at C-4 or C-5 of the thiophene afforded inhibitors with low nanomolar potency. Optimization of the thiophene substituent at C-4 afforded subnanomolar inhibitors with improved in vitro anticoagulant activity. Incorporating basic amine substituents on the thiophene increased hydrophilicity and improved anticoagulant activity. The pharmacokinetic profile of one inhibitor was evaluated in dogs, and the X-ray crystal structure of this compound bound to factor Xa provides insight into the observed SAR for binding to factor Xa. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.12.019
• 作为产物：
  描述：

  3-氨基-5-甲基噻吩-2-羧酸甲酯 在 盐酸 、 甲醇 、 水 、 lithium hydroxide 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 3.17h， 生成 3-氯-5-甲基-2-噻吩甲酸
  参考文献：
  名称：

  [EN] THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF
  [FR] AGONISTE DU RÉCEPTEUR DE GLP-1 DE TYPE THIOPHÈNE ET SON UTILISATION
  [ZH] 噻吩类GLP-1受体激动剂及其用途

  摘要：

  提供了一系列噻吩类GLP-1受体激动剂化合物，其制备方及制药用途，所述的化合物（I）能用于制备治疗或预防GLP-1介导的疾病及相关疾病。

  公开号：

  WO2022199458A1

文献信息

• [EN] 5-(THIOPHEN-2-YL)-1H-TETRAZOLE DERIVATIVES AS BCKDK INHIBITORS USEFUL FOR TREATING VARIOUS DISEASES<br/>[FR] DÉRIVÉS DE 5-(THIOPHÉN-2-YL) -1H-TÉTRAZOLE UTILISÉS EN TANT QU'INHIBITEURS DE BCKDK UTILES POUR LE TRAITEMENT DE DIVERSES MALADIES
  申请人：PFIZER

  公开号：WO2020261144A1

  公开（公告）日：2020-12-30

  Described herein are compounds of Formula (I), wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.

  本文描述的是式（I）化合物，其中R1、R2和R3如本文所定义，它们作为支链α酮酸脱氢酶激酶抑制剂的用途，含有这些抑制剂的药物组合物，以及利用这些抑制剂治疗糖尿病、NASH和心力衰竭等疾病。
• Ortho-anthranilamide derivatives as anti-coagulants
  申请人：Berlex Laboratories, Inc.

  公开号：US06498185B1

  公开（公告）日：2002-12-24

  This invention is directed to compounds of formula (III): wherein B, C, D, E, R1, R2 and R3 are disclosed herein. These compounds are disclosed as being useful as anti coagulants.

  本发明涉及式（III）化合物：其中B，C，D，E，R1，R2和R3在此披露。这些化合物被披露为有用的抗凝剂。
• HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS
  申请人：OWADA Shingo

  公开号：US20080027068A1

  公开（公告）日：2008-01-31

  A compound represented by the formula (1): wherein A is a nitrogen atom or CR 4 , B is an oxygen atom, a sulfur atom or NR 9 (provided that when A is a nitrogen atom, B is not NH), R 1 is a C 2-14 aryl group, L 1 is a bond, CR 10 R 11 , an oxygen atom, a sulfur atom or NR 12 , X is OR 13 , SR 13 or NR 14 NR 15 , R 2 is a hydrogen atom, a formyl group, a C 1-10 alkyl group or the like, L 2 is a bond or the like, L 3 is a bond, CR 17 R 18 , an oxygen atom, a sulfur atom or NR 19 , L 4 is a bond, CR 20 R 21 , an oxygen atom, a sulfur atom or NR 22 , Y is an oxygen atom, a sulfur atom or NR 23 , and R 3 is a C 2-14 aryl group, a tautomer, prodrug or is pharmaceutically acceptable salt of the compound or a solvate thereof.

  化合物的化学式为（1）：其中A是氮原子或CR4，B是氧原子、硫原子或NR9（但当A是氮原子时，B不是NH），R1是C2-14芳基基团，L1是键，CR10R11、氧原子、硫原子或NR12，X是OR13、SR13或NR14NR15，R2是氢原子、甲酰基、C1-10烷基或类似物，L2是键或类似物，L3是键，CR17R18、氧原子、硫原子或NR19，L4是键，CR20R21、氧原子、硫原子或NR22，Y是氧原子、硫原子或NR23，R3是C2-14芳基基团，化合物的互变异构体、前药或药学上可接受的盐或其溶剂。
• N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS
  申请人：Idorsia Pharmaceuticals Ltd

  公开号：EP3928836A1

  公开（公告）日：2021-12-29

  The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

  本发明涉及式 (I) 的衍生物 其中 (R1)n、R2、R3、R4a、R4b、R5a、R5b 和 Ar1 如说明书所述，涉及它们的制备、它们的药学上可接受的盐，以及它们作为药物的用途、含有一种或多种式 (I) 化合物的药物组合物，特别是它们作为前列腺素 2 受体 EP2 和/或 EP4 的调节剂的用途。
• N-substituted indole derivatives as PGE2 receptor modulators
  申请人：Idorsia Pharmaceuticals Ltd

  公开号：US11241431B2

  公开（公告）日：2022-02-08

  The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

  本发明涉及式 (I) 的衍生物 其中 (R1)n、R2、R3、R4a、R4b、R5a、R5b 和 Ar1 如说明书所述，涉及它们的制备、它们的药学上可接受的盐，以及它们作为药物的用途、含有一种或多种式 (I) 化合物的药物组合物，特别是它们作为前列腺素 2 受体 EP2 和/或 EP4 的调节剂的用途。